is a partner at Axinn, Veltrop & Harkrider LLP. Ted’s practice focuses on patent litigation and he has experience litigating antitrust and other commercial matters. Clients frequently turn to Ted for guidance on issues covering patent damages and other remedies, and competition-related issues that arise in connection with patent disputes.
For more information or to contact Ted, please visit his Firm Profile Page.
The University of California (“UC”) and The Broad Institute, Inc. (“Broad”) are among the leaders in the development of CRISPR technology. Both UC and Broad filed patent applications for claims broadly drawn to CRISPR-Cas9 systems and methods of DNA editing. These parties are currently engaged in litigation over patents concerning the potentially most lucrative application of CRISPR technology – the use of CRISPR-Cas9 in plant and animal (eukaryotic) cells. The outcome of this litigation will affect control of the CRISPR platform and development of the technology.